Getmedicin.org

Codeine sulfate 30 mg tablets





CODEINE SULFATE 30 mg - DailyMed

11/21/2014
08:09 | Author: Tyler James

Codeine sulfate 30 mg tablets
CODEINE SULFATE 30 mg - DailyMed

Each tablet contains: Codeine Sulfate 30 or 60 mg. Chemically, Codeine Sulfate is, Morphinan-6-ol,7,8-didehydro-4,5-epozy-3-methoxy-17- methyl-,(5_,6_).

The administration of codeine or other narcotics may obscure the diagnosis or clinical course in patients with acute abdominal conditions.

60 mg, bottles of 100 (NDC, Imprinted LV on one side and 906 on the other side).

Cardiovascular – Flushing of the face, bradycardia, palpitation, faintness, and syncope.

The major effects of codeine are on the central nervous system and the bowel.

Comments (1)Read more



Acetaminophen and Codeine Phosphate Tablets, USP CIII 30030mg

9/20/2014
06:42 | Author: Hannah Ramirez

Codeine sulfate 30 mg tablets
Acetaminophen and Codeine Phosphate Tablets, USP CIII 30030mg

Acetaminophen & Codeine Phosphate Tablets, USP CIII 300/30 mg WARNING: Death Related to Ultra-Rapid Metabolism of Codeine to Morphine. Respiratory.

WARNING: Death Related to Ultra-Rapid Metabolism of Codeine to Morphine.

INDICATIONS AND DOSAGE.

USE IN SPECIFIC POPULATIONS.

For additional information on Acetaminophen & Codeine Phosphate Tablets, USP CIII 300/30 mg, call Customer Service at 1.800.325.8888 or Medical Information at 1.800.778.7898.

Respiratory depression and death have occurred in children who received codeine following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine due to a CYP2D6 polymorphism. CONTRAINDICATIONS WARNINGS AND PRECAUTIONS ADVERSE REACTIONS.

Mallinckrodt Pharmaceuticals is a registered business name of Mallinckrodt plc, which is registered in Ireland as a public limited company with registration number 522227 and has its registered office at Damastown, Mulhuddart, Dublin 15, Ireland.

Acetaminophen and Codeine Phosphate Tablets, USP (CIII) are indicated for the relief of mild to moderay severe pain. WARNING: Hepatotoxicity.

Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 milligrams per day, and often involve more than one acetaminophen-containing product.

Tylenol is a registered trademark of The Tylenol Company.

This information is intended for U.S.healthcare professionals only.

Mallinckrodt, the 'M' brand mark, the Mallinckrodt Pharmaceuticals logo and other brands are trademarks of a pany. 2014 Mallinckrodt.

Comments (0)

Lannett Receives FDA Approval for Codeine Sulfate Tablets USP

7/19/2014
04:13 | Author: Sarah Gray

Codeine sulfate 30 mg tablets
Lannett Receives FDA Approval for Codeine Sulfate Tablets USP

Codeine Sulfate Tablets USP 15 mg, 30 mg and 60 mg is our second product approved by the FDA thus far in 2014,” said Arthur P. Bedrosian.

This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Any such statement, including, but not limited to, successfully commercializing Codeine Sulfate Tablets USP 15 mg, 30 mg and 60 mg, and the receipt of product approvals in coming months, whether expressed or implied, is subject to market and other conditions, and subject to risks and uncertainties which can cause actual results to differ materially from those currently anticipated due to a number of factors which include, but are not limited to, the risk factors discussed in the Company’s Form 10-K and other documents filed with the SEC from time to time, including the prospectus supplement related to the proposed offering to be filed with the SEC.

Comments (3)Read more

Lannett Receives FDA Approval for Codeine Sulfate Tablets USP

5/18/2014
02:04 | Author: Emily Peterson

Codeine sulfate 30 mg tablets
Lannett Receives FDA Approval for Codeine Sulfate Tablets USP

Codeine Sulfate Tablets USP 15 mg, 30 mg and 60 mg is our second product approved by the FDA thus far in 2014,” said Arthur P. Bedrosian.

Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications. For more information, visit the company’s website at www.lannett.com.

This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Any such statement, including, but not limited to, successfully commercializing Codeine Sulfate Tablets USP 15 mg, 30 mg and 60 mg, and the receipt of product approvals in coming months, whether expressed or implied, is subject to market and other conditions, and subject to risks and uncertainties which can cause actual results to differ materially from those currently anticipated due to a number of factors which include, but are not limited to, the risk factors discussed in the Company’s Form 10-K and other documents filed with the SEC from time to time, including the prospectus supplement related to the proposed offering to be filed with the SEC.

Comments (4)Read more

Codeine Sulfate Tablets, 30 mg 60 mg

3/17/2014
12:15 | Author: Sarah Gray

Codeine sulfate 30 mg tablets
Codeine Sulfate Tablets, 30 mg 60 mg

Products: Codeine Sulfate Tablets. 30 mg & 60 mg. Dear Mr. Moshal: This letter is written in reference to your firm's marketing of an unapproved new drug in.

As described in the guidance entitled "Marketed Unapproved Drugs - Compliance Policy Guide"1 the Agency may exercise its enforcement discretion and identify a period of time during which the Agency does not intend to initiate an enforcement action against a currently marketed unapproved drug. FDA does not intend to initiate enforcement actions related to your unapproved drug products, Codeine Sulfate Tablets, 30 mg & 60 mg, which are being manufactured as of the date of this letter, unless the manufacturing of these products continues more than 90 days after the date of this letter.

Comments (5)Read more